1. Home
  2. TCMD vs FULC Comparison

TCMD vs FULC Comparison

Compare TCMD & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$31.49

Market Cap

533.5M

Sector

Health Care

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
FULC
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.5M
467.8M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
TCMD
FULC
Price
$31.49
$3.77
Analyst Decision
Strong Buy
Buy
Analyst Count
4
8
Target Price
$36.00
$16.38
AVG Volume (30 Days)
223.1K
3.4M
Earning Date
05-04-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
17.14
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.60
N/A
Revenue Next Year
$9.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.42
$2.83
52 Week High
$37.77
$15.74

Technical Indicators

Market Signals
Indicator
TCMD
FULC
Relative Strength Index (RSI) 75.14 39.46
Support Level $25.34 $2.83
Resistance Level $37.77 $4.02
Average True Range (ATR) 1.27 0.23
MACD 0.43 0.14
Stochastic Oscillator 87.85 57.26

Price Performance

Historical Comparison
TCMD
FULC

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: